Anthos Therapeutics

Anthos Therapeutics

  • Founded: 2018
  • Location: Cambridge, MA
  • Employee range: 11 - 50
  • Clinical stage: Clin3 (fast track)
  • Therapy area: Cancer associated thrombosis (FT)
  • Drug types: HEM, CVV
  • Lead product: Abelacimab
  • Product link:
  • Funding: $250M Feb 2019
  • Investors: Blackstone, Novartis

job board

Short description:

Antibody Therapeutics

Drug notes:

Also Clin3 (fast track) stroke and embolism in atrial fibrillation, Clin2 venous thromboembolism

Long description:

Anthos is a clinical stage biopharmaceutical company based in Cambridge, MA that was launched in 2019 by Blackstone Life Sciences. They are focused on developing and validating therapeutics for cardiovascular and metabolic diseases. Anthos hopes to significantly reduce the prevalence of stroke and heart attack by offering an alternative to traditional anticoagulants, which have limited use due to their increased potential for bleeding events.


© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy